Asia's Premier Event Exclusively for CDMOs!

Christopher Pawlak, Ph.D., had almost 2 decades in leadership position managing External Manufacturing and CDMOs in Pharmaceutical markets all over the globe. He oversaw global supplier management, external manufacturing operations, and strategic partnerships across the company’s biopharmaceutical network, manage finance of external manufacturing network. With over two decades of experience in pharmaceutical supply chain and procurement, he has led initiatives to enhance supplier performance, drive operational efficiency, and foster intercultural collaboration in global manufacturing.

In addition to his industry leadership, Dr. Pawlak serves as a lecturer and Executive Council member at the St. Gallen Integrated IMT Business School, reflecting his ongoing commitment to education and executive development. He is widely recognized as a thought leader in strategic supplier management, intercultural collaboration, and biomanufacturing innovation. 

Dr. Jimmy Chang is an accomplished biopharmaceutical executive and scientist with over three decades of global experience spanning drug development, clinical development, regulatory strategy, and commercialization. He currently serves as the President and Chief Executive Officer of TaiMed Biologics, a publicly traded company on the Taiwan Stock Exchange and a recognized innovator in HIV treatment.

Under Dr. Chang’s leadership, TaiMed successfully achieved U.S. FDA approval and commercialization of Trogarzo® (ibalizumab)—the world’s first and only long-acting monoclonal antibody for the treatment of HIV, marking a breakthrough in the fight against multidrug-resistant HIV. His strategic vision has helped transform TaiMed from a development-stage enterprise into a fully integrated, commercial-stage biopharmaceutical company. The company now boasts capabilities in antibody innovation, antibody-drug conjugates (ADCs), CDMO services, and operates its own GMP biologics manufacturing facility in Taiwan.

Dr. Lin is a biomedical scientist with over 20 years of experience in life science industries, spanning medical devices, pharmaceuticals, biomaterials, and biochips. He previously served as Deputy Project Director at Taiwan’s ITRI, leading global strategic alliances. As Senior VP at Body Organ Biomedical Inc., he expanded operations across Taiwan, China, and the Netherlands, establishing sales networks and securing regulatory approvals.

He led cross-border R&D collaborations, securing a €300,000 SenterNovem grant in 2009, and successfully filed 36 patents through joint research. Earlier, he also completed Taiwan's first bone filler registration. Dr. Lin holds a Ph.D. in Bioengineering from National Taiwan University and an MBA from National Chengchi University.

Zach Pang is Group Leader at the Bioprocessing Technology Institute, A*STAR and Senior Scientist at the Bioinformatics Institute, A*STAR, where he leads a research team to drive digitalisation in biomanufacturing. His research interests include mechanistic modelling and process modelling of bioprocesses. He is also Assistant Professor (adj) at NUS Department of Biomedical Engineering and NTU School of Chemistry, Chemical Engineering, and Biotechnology. Zach is also a co-founder and chief scientific advisor of AuctuCel Pte Ltd, a biotech company that develops AI-powered and ready-to-use culture media to improve biomanufacturing yield. 

Zach developed an interest in cross-disciplinary research when he was pursuing his Bachelor of Technology in Mechanical Engineering at the National University of Singapore, where he did his undergraduate research on cancer cell mechanics. He later pursued a PhD in Bioengineering at Imperial College London under the A*STAR Scholarship, and more recently completed a Doctor of Business Administration (DBA) from the Swiss School of Management. Zach Pang also holds a Master of Business Administration from Quantic School of Business and Technology and a postgraduate certificate in learning and teaching in higher education from the University of London. He is a chartered engineer (CEng) with the Engineering Council UK, an associate fellow of the Higher Education Academy, UK (AFHEA) and a member of the Institute of Physics and Engineering in Medicine (MIPEM).

Dr. Warren Chan is the Dean of the College of Engineering and the President’s Chair Professor in Engineering at Nanyang Technological University (NTU). He received his B.S. degree from the University of Illinois in 1996, Ph.D. from Indiana University in 2001, post-doctoral training at the University of California (San Diego). He started as an Assistant Professor at the University of Toronto from 2002, became Full professor in 2012, and the Canadian Research Chair in Nanoengineering. He was the Director of the Institute of Biomedical Engineering before joining NTU. His lab develops nanotechnology for diagnosing and treating cancer and infectious diseases. He is an Executive Editor of ACS Nano. 

20+ years driving operational transformation in pharma/biotech, optimising E2E processes (S&OP, network design, product launch) through data integration, digital tools, and cross-functional collaboration. Proven success in change management, cost reduction, supplier management, tech transfer leader for drug product (aseptic processes), and M&A integration within complex matrix environments. Focused on building scalable, patient-centric supply chains. Adept at balancing functional priorities with enterprise strategy while influencing stakeholders at all levels. Passionate about leveraging AI and advanced analytics to enhance decision-making and operational agility. Let’s connect to discuss the future of intelligent pharma operations.